Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xigris Medicare “Add-On” Payments Approved; CMS Estimates 50,000 Cases

Executive Summary

The Centers for Medicare & Medicaid Services is estimating that the Medicare market for Lilly's Xigris will be $340 mil. in fiscal year 2003
Advertisement

Related Content

CMS predicts fewer Xigris patients
CMS predicts fewer Xigris patients
Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent
Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent
Zyvox Medicare “Add-On” Payments Denied; CMS Wary Of Precedent
Lilly Xigris Add-On Medicare Payment Decision Awaits Further CMS Analysis
Lilly Foresees No Zyprexa Diabetes Warning In U.S.; Pfizer Sees Opening
Lilly Foresees No Zyprexa Diabetes Warning In U.S.; Pfizer Sees Opening
Xigris Growth Tied To Patient Selection As Hospitals Wrestle With Protocols
Lilly Xigris Price Is $6,800 Per Dose; Sepsis Agent Clears FDA
Advertisement
UsernamePublicRestriction

Register

PS040283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel